Trump's GLOBE Drug Pricing Rule Saves 96% Less Than Proposed — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- The Trump administration published a final rule called GLOBE (Global Benchmark for Efficient Drug Pricing) targeting Medicare prices for drugs administered in doctor offices, with the program applying to only four companies.
- GLOBE delivers 96% less in savings than the administration's initial proposal, according to STAT+.
- The GLOBE pilot is one of two mandatory most-favored-nation pricing programs in Trump's drug pricing push; the other, called GUARD, remains in the proposed stage.
- Drugmakers that struck separate voluntary deals with the administration to offer MFN prices on Medicaid drugs are exempt from the GLOBE pilot under the final rule's terms.
- The policy aims to align Medicare drug prices with the levels charged in other wealthy countries, the core of the most-favored-nation pricing framework.
Why it matters: By narrowing the mandatory pilot to just four companies and exempting every drugmaker that signed a voluntary Medicaid MFN deal, the administration has shrunk the program's reach so dramatically that it achieves a fraction of the savings originally projected. Taxpayers and Medicare patients expecting meaningful price relief from most-favored-nation benchmarking will see minimal impact, while the four remaining companies are now the sole targets of mandatory foreign-price benchmarking.
Ask SkimNews
